Oxford Heartbeat
Oxford Heartbeat is a pioneering company that develops advanced AI technology for surgical planning, specifically through its flagship product, PreSize® Neurovascular. This decision-support software assists clinicians in real-time by creating patient-specific blood vessel models from routine scans, allowing for precise implant selection and surgical rehearsal. With a mission to enhance surgical outcomes and reduce complications, Oxford Heartbeat is actively involved in clinical trials across multiple UK hospitals, demonstrating significant traction and validation in the healthcare sector.
Oxford Heartbeat
Oxford Heartbeat is a pioneering company that develops advanced AI technology for surgical planning, specifically through its flagship product, PreSize® Neurovascular. This decision-support software assists clinicians in real-time by creating patient-specific blood vessel models from routine scans, allowing for precise implant selection and surgical rehearsal. With a mission to enhance surgical outcomes and reduce complications, Oxford Heartbeat is actively involved in clinical trials across multiple UK hospitals, demonstrating significant traction and validation in the healthcare sector.
TL;DR
Product: PreSize® Neurovascular — patient-specific virtual vessel modelling and implant simulation
Regulatory: CE marked (Class I Measuring) and ISO 13485 certified
Founder / CEO: Dr. Katerina Spranger
Founded: 2015
Funding type: Primarily grant funding and accelerator awards (e.g., Innovate UK)
Company Overview
Problem Domain
Neurovascular surgical planning and device selection
Founded
2015
Industry
Biotechnology
Funding Track Record
Crunchbase lists a Grant dated 4 Aug 2021 with Innovate UK as lead funder; company has received multiple grants and accelerator awards including a ~£1.5M Innovate UK Biomedical Catalyst award announced Nov 2021.
Investor Signal
“Grant-led funding from public and accelerator programmes (Innovate UK, SBRI Healthcare, EIT Health, DigitalHealth.London Accelerator, MassChallenge, Pitch@Palace)”